文献速递临床试验与 GCP流行病学与生物统计

晚期肺结核治疗试验终点定义的系统综述

A systematic review of endpoint definitions in late phase pulmonary tuberculosis therapeutic trials.
PubMed 文献 · Trials · 2021-08-03

该系统综述检索了WHO ICTRP等注册平台,纳入31项1995年至今、随访≥100例的肺结核治疗试验,审查其方案与统计分析计划。发现 favourable 与 unfavourable 结局定义虽大体共识但细节异质,死亡常按病因条件解释,退出/失访处理不一致,呼吁按ICH E9(R1)实现结局标准化。

要点

  • 肺结核治疗试验的复合二分类结局定义异质,缺乏标准化。
  • favourable 结局处理最一致,但具体规定差异大。
  • 死亡常按病因条件解释,退出/失访是结局判读难点。

核心结论

  • 31项肺结核治疗试验的结局定义异质,需更清晰规定并推动通用标准化。
  • ICH E9(R1)附则为实现结局标准化提供指南。

研究设计与样本

  • 系统综述,主要从WHO ICTRP识别试验,纳入收集治疗后随访数据且入组至少100例患者的试验。
  • 从研究者获取1995年至今符合条件试验的方案与统计分析计划(SAP),提取并归类结局定义。
  • 从2205项与TB相关的试验中选出51项进行方案与SAP审查,最终31项符合条件且有可获取文档。

主要发现

  • 在favourable、unfavourable与not assessable三大类内,favourable与unfavourable定义有广泛共识,但具体细节并非总是提供,明确处理时亦异质。
  • favourable结局处理最一致,但具体规定差异大。
  • 部分情况下同一事件在不同方案中定义不同,尤其区分unfavourable与not assessable事件时。
  • 死亡常被解释为取决于病因。
  • 因退出或失访未完成研究的患者,给结局的一致解释与分析处理带来特殊挑战。

临床怎么用

  • 解读肺结核治疗试验结果时需核查其结局定义与SAP,注意favourable、unfavourable与not assessable的界定差异。
  • 设计或报告此类试验时可参照ICH E9(R1)附则,明确死亡归因及退出/失访的结局处理规则。

局限性

  • 仅31项试验符合条件且有可获取文档,方案与SAP获取可能受限。
  • 结局定义细节并非总是提供,明确处理时亦异质,影响归类比较。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Safe, more efficacious treatments are needed to address the considerable morbidity and mortality associated with pulmonary tuberculosis (TB). However, the current practice in TB therapeutics trials is to use composite binary outcomes, which in the absence of standardization may inflate false positive and negative errors in evaluating regimens. The lack of standardization of outcomes is a barrier to the identification of highly efficacious regimens and the introduction of innovative methodologies METHODS: We conducted a systematic review of trials designed to advance new pulmonary TB drugs or regimens for regulatory approval and inform practice guidelines. Trials were primarily identified from the WHO International Clinical Trial Registry Platform (ICTRP). Only trials that collected post-treatment follow-up data and enrolled at least 100 patients were included. Protocols and Statistical Analysis Plans (SAP) for eligible trials from 1995 to the present were obtained from trial investigators. Details of outcome data, both explicit and implied, were abstracted and organized into three broad categories: favorable, unfavorable, and not assessable. Within these categories, individual trial definitions were recorded and collated, and areas of broad consensus and disagreement were identified and described. RESULTS: From 2205 trials in any way related to TB, 51 were selected for protocol and SAP review, from which 31 were both eligible and had accessible documentation. Within the three designated categories, we found broad consensus in the definitions of favorable and unfavorable outcomes, although specific details were not always provided, and when explicitly addressed, were heterogeneous. Favorable outcomes were handled the most consistently but were widely variable with respect to specification. In some cases, the same events were defined differently by different protocols, particularly in distinguishing unfavorable from not assessable events. Death was often interpreted as conditional on cause. Patients who did not complete the study because of withdrawal or loss to follow-up presented a particular challenge to consistent interpretation and analytic treatment of outcomes. CONCLUSIONS: In a review of 31 clinical trials, we found that outcome definitions were heterogeneous, highlighting the need to establish clearer specification and a move towards universal standardization of outcomes across pulmonary TB trials. The ICH E9 (R1) addendum provides guidelines for undertaking and achieving this goal. PROSPERO REGISTRATION: PROSPERO CRD42020197993 . Registration 11 August 2020.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Hills NK, Lyimo J, Nahid P, et al. A systematic review of endpoint definitions in late phase pulmonary tuberculosis therapeutic trials. Trials. 2021. PMID: 34344435. doi:10.1186/s13063-021-05388-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。